Free Trial

Aditxt (ADTX) Stock Price, News & Analysis

-0.02 (-0.99%)
(As of 03:21 PM ET)
Today's Range
50-Day Range
52-Week Range
23,495 shs
Average Volume
276,058 shs
Market Capitalization
P/E Ratio
Dividend Yield
Price Target

Aditxt MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
2,934.8% Upside
$61.00 Price Target
Short Interest
8.85% of Float Sold Short
Dividend Strength
News Sentiment
0.25mentions of Aditxt in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.02 out of 5 stars

ADTX stock logo

About Aditxt Stock (NASDAQ:ADTX)

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

ADTX Stock Price History

ADTX Stock News Headlines

Appili Therapeutics To Be Acquired By Aditxt
Aditxt CEO Provides Short-Term Loan to Bolster Stability
Aditxt Stock (NASDAQ:ADTX), Short Interest Report
See More Headlines
Receive ADTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aditxt and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$67.18 per share


Free Float
Market Cap
No Data
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

ADTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Aditxt stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aditxt in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADTX shares.
View ADTX analyst ratings
or view top-rated stocks.

What is Aditxt's stock price target for 2024?

1 brokers have issued twelve-month target prices for Aditxt's stock. Their ADTX share price targets range from $61.00 to $61.00. On average, they predict the company's stock price to reach $61.00 in the next twelve months. This suggests a possible upside of 2,934.8% from the stock's current price.
View analysts price targets for ADTX
or view top-rated stocks among Wall Street analysts.

How have ADTX shares performed in 2024?

Aditxt's stock was trading at $6.63 at the start of the year. Since then, ADTX shares have decreased by 69.7% and is now trading at $2.01.
View the best growth stocks for 2024 here

When is Aditxt's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our ADTX earnings forecast

How were Aditxt's earnings last quarter?

Aditxt, Inc. (NASDAQ:ADTX) posted its quarterly earnings data on Wednesday, August, 11th. The company reported ($840.00) EPS for the quarter, missing analysts' consensus estimates of ($100.00) by $740.00. Aditxt had a negative net margin of 5,016.31% and a negative trailing twelve-month return on equity of 927.61%.

When did Aditxt's stock split?

Shares of Aditxt reverse split on the morning of Friday, August 18th 2023. The 1-40 reverse split was announced on Friday, August 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Aditxt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aditxt investors own include Tesla (TSLA), Dynavax Technologies (DVAX), Boeing (BA), CrowdStrike (CRWD), Genius Brands International (GNUS), Nikola (NKLA), Block (SQ), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV) and Arbutus Biopharma (ABUS).

Who are Aditxt's major shareholders?

Aditxt's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Amro A Albanna, Paribas Securities Corp Bnp and Shahrokh Shabahang.
View institutional ownership trends

How do I buy shares of Aditxt?

Shares of ADTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADTX) was last updated on 5/28/2024 by Staff

From Our Partners